Autopsy report · NCT05497336

A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

“company development strategy adjustment”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 5 months before it stopped.
• 8 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Sponsor type

Industry

Conditions

Colorectal Cancer

Interventions

IBI351; Cetuximab

Participants

8

Sites

1

Countries

China

Trials that died the same way

• Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
  “Company development strategy change” (92% match in meaning)
• IBI397 or Combination Therapies in Patients With Advanced Malignancies
  “Due to the company's development strategy adjustment” (84% match in meaning)
• A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors
  “Research and development strategy adjustment” (80% match in meaning)
• Evaluation of Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft in Treatment of Partial Thickness Thermal Burns
  “Change in company strategy.” (76% match in meaning)
• A Clinical Investigation to Assess the Effectiveness of Benzocaine Condoms in Healthy Adult Men
  “Change of the product development strategy” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.